Home / Healthcare/ 3M to buy medical device maker Acelity in $ 6.7 b deal

3M to buy medical device maker Acelity in $ 6.7 b deal

Comments / {{hitsCtrl.values.hits}} Views / Tuesday, 7 May 2019 00:00


Reuters: 3M Co said yesterday it would buy privately held medical device maker Acelity Inc in a deal valued at $ 6.7 billion, including debt, as the US industrial conglomerate looks to expand its business in medical dressings and related products. 

The maker of Post-It notes and Scotch tape is buying the company and some of its units from a consortium of funds advised by Apax Partners, affiliates of Canada Pension Plan Investment Board and the Public Sector Pension Investment Board. 

Acelity, under its KCI brand, makes advanced wound dressings and specialised systems that use a vacuum to seal off acute or chronic wounds, promoting faster healing. 

The company reported revenue of $ 1.5 billion in 2018, nearly 80% of which came from sales of such specialised systems that provide ‘negative pressure wound therapy’. 

3M said the acquisition would boost its presence in the advanced wound care market, which is valued at more than $ 8 billion and is growing at a rate of 4-6% annually. 

The purchase price values Acelity at 15 times its 2018 adjusted earnings before interest, tax, depreciation and amortisation, 3M said. 

Acelity will become part of 3M’s medical solutions business that makes medical tapes, sterilisation products and acute wound care dressings products. The deal is expected to close in the second half of 2019. 

Excluding one-time expenses, 3M expects the deal to add 25 cents per share to its earnings in the first year following the closure of the deal. 

3M also said it now expects full-year 2019 share buyback program to be in the range of $ 1 billion to $ 1.5 billion, compared with a prior range of $ 2 billion to $ 4 billion. 

The company’s stock was down about 1% at $ 184.23 before the bell. 

Credit Suisse was financial adviser to 3M, while Cleary Gottlieb Steen & Hamilton LLP was its legal counsel. 

J.P. Morgan and Goldman Sachs were the consortium’s financial advisers, with Simpson Thacher & Bartlett LLP and Jackson Walker LLP acting as its legal advisers.

Share This Article

Facebook Twitter


1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.


Today's Columnists

Trendvertising: The new world of communication in a hashtag world

Tuesday, 20 August 2019

Rahul Bose, an Indian actor, caught a lot of attention for a video post that went viral, where he complained about the price of bananas during his stay at a five-star hotel in Mumbai. As he explained in his story – he went to the gym at his hotel w

Company Law intertwined with Income Tax – Understanding the nexus! Part II

Tuesday, 20 August 2019

A comparison and analysing the impact of corresponding provisions of Companies Act No. 7 of 2007 and Inland Revenue Act No. 24 of 2017 reveals invaluable insights corporate management must be aware of in day-to-day management activities as well as st

Will ‘10 February’ be repeated?

Tuesday, 20 August 2019

Whilst Sri Lanka is in election mode, the thought crossing every Sri Lankans mind is, ‘Will the 10 February 2018 elections behaviour be repeated?’ given the head-start that ‘Brand Gota’ has got. Whilst many are speculating who will be the fig

Shanta Devarajan: Economist who cannot get disconnected from his motherland

Monday, 19 August 2019

For me, Shanta Devarajan, formerly the Acting Chief Economist of the World Bank Group succeeding the Nobel Laureate Paul Romer and presently Professor at Georgetown University, USA, was a legend by himself. When I met him in early part of the new mil

Columnists More

Special Report